Therapeutic potential of biologics in prurigo nodularis

References

• Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059–1065.
   PubMed Web of Science ®Google Scholar
• Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: united States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747–760.
   PubMed Web of Science ®Google Scholar
• Pereira MP, Zeidler C, Wallengren J, et al. Chronic Nodular Prurigo: a European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. Acta Derm Venereol. 2020;34(10):2373–2383.
   Google Scholar
• Zeidler C, Tsianakas A, Pereira M, et al. Chronic Prurigo of Nodular Type: a Review. Acta Derm Venereol. 2018;98(2):173–179.
   PubMed Web of Science ®Google Scholar
• Fostini AC, Girolomoni G, Tessari G. Prurigo nodularis: an update on etiopathogenesis and therapy. J Dermatolog Treat. 2013;24(6):458–462.
   PubMed Web of Science ®Google Scholar
• Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol. 2005;46(4):211–218. quiz 219–20.
   PubMed Web of Science ®Google Scholar
• Zeidler C, Yosipovitch G, Ständer S. Prurigo Nodularis and Its Management. Dermatol Clin. 2018;36(3):189–197.
   PubMed Web of Science ®Google Scholar
• Boozalis E, Tang O, Patel S, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol. 2018;79(714–719):e3.
   PubMed Web of Science ®Google Scholar
• Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559–1565.
   PubMed Web of Science ®Google Scholar
• Gwillim EC, Janmohamed SR, Yousaf M, et al. The impact of prurigo nodularis on sleep disturbance and related impact: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(12):e815–e817.
   PubMed Web of Science ®Google Scholar
• Jørgensen KM, Egeberg A, Gislason GH, et al. Anxiety, depression and suicide in patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2017;31(2):e106–e107.
   PubMed Web of Science ®Google Scholar
• Pereira MP, Hoffmann V, Weisshaar E, et al. Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J Eur Acad Dermatol Venereol. 2020;34(10):2373–2383.
   PubMed Web of Science ®Google Scholar
• Kwatra SG. Breaking the Itch-Scratch Cycle in Prurigo Nodularis. N Engl J Med. 2020;382(8):757–758.
   PubMed Web of Science ®Google Scholar
• Dalgard FJ, Å S, Halvorsen JA, et al. Itch and Mental Health in Dermatological Patients across Europe: a Cross-Sectional Study in 13 Countries. J Invest Dermatol. 2020;140(3):568–573.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Aiba S, Matsumura N, et al. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic. Dermatology. 1995;190(4):269–276.
   PubMed Web of Science ®Google Scholar
• Ständer S, Yosipovitch G, Legat FJ, et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. N Engl J Med. 2020;382(8):706–716.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83(1):39–45.
   PubMed Web of Science ®Google Scholar
• Silvestre Salvador JF, Romero-Pérez D, Atopic E-DB. Dermatitis in Adults: a Diagnostic Challenge. J Investig Allergol Clin Immunol. 2017;27(2):78–88.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Scalvenzi M, et al. Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis. Dermatitis. 2020;31(1):81–84.
   PubMed Web of Science ®Google Scholar
• Tilotta G, Pistone G, Caruso P, et al. Our experience with prurigo nodularis treated with dupilumab. J Eur Acad Dermatol Venereol. 2021;35(4):285-287.
   PubMed Web of Science ®Google Scholar
• Agelopoulos K, Rülander F, Dangelmaier J, et al. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK 1/2 activation. J Eur Acad Dermatol Venereol. 2019;33(12):2371–2379.
   PubMed Web of Science ®Google Scholar
• Larson VA, Tang O, Ständer S, et al. Association between itch and cancer in 16,925 patients with pruritus: experience at a tertiary care center. J Am Acad Dermatol. 2019;80(4):931–937.
   PubMed Web of Science ®Google Scholar
• Huang AH, Canner JK, Khanna R, et al. Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases. J Invest Dermatol. 2020;140(480–483):e4.
   Google Scholar
• Ständer HF, Elmariah S, Zeidler C, et al. Diagnostic and treatment algorithm for chronic nodular prurigo. J Am Acad Dermatol. 2020;82(2):460–468.
   PubMed Web of Science ®Google Scholar
• Huang AH, Canner JK, Williams KA, et al. Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis. Br J Dermatol. 2020;183(1):182–184.
   PubMed Web of Science ®Google Scholar
• Williams KA, Huang AH, Belzberg M, et al. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol. 2020;83(6):1567–1575.
   PubMed Web of Science ®Google Scholar
• Williams KA, Roh YS, Brown I, et al.Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021;14(1):67–77.
   PubMed Web of Science ®Google Scholar
• Zeidler C, Ständer S. The pathogenesis of Prurigo nodularis–’Super-Itch’ in exploration. Eur J Pain. 2016;20(1):37–40.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Rosen JD, Itch HT. From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142(5):1375–1390.
   PubMed Web of Science ®Google Scholar
• Zhong W, Wu X, Zhang W, et al. Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo Nodularis. Acta Derm Venereol. 2019;99(6):579–586.
   PubMed Web of Science ®Google Scholar
• Pereira MP, Pogatzki-Zahn E, Snels C, et al. There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations. Exp Dermatol. 2017;26(10):969–971.
   PubMed Web of Science ®Google Scholar
• Raap U, Günther C. Pathogenese der Prurigo nodularis. Hautarzt. 2014;65(8):691–696.
   PubMed Web of Science ®Google Scholar
• Weigelt N, Metze D, Ständer S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol. 2010;37(5):578–586.
   PubMed Web of Science ®Google Scholar
• Ringkamp M, Meyer R. Pruriceptors. In: Carstens E, Akiyama T, editors. Itch: Mechanisms and Treatment. Boca Raton (FL): CRC Press/Taylor & Francis; 2014. Chapter 9.
   Google Scholar
• Park K, Mori T, Nakamura M, et al. Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo. Eur J Dermatol. 2011;21(1):135–136.
   PubMed Web of Science ®Google Scholar
• Wong L-S, Yen Y-T, Lin S-H, et al. 17A Induces Endothelin-1 Expression through p38 Pathway in Prurigo Nodularis. J Invest Dermatol. 2020;140(702–706):e2.
   Google Scholar
• Belzberg M, Alphonse MP, Brown I, et al. Prurigo Nodularis is Characterized by Systemic and Cutaneous Th22 Immune Polarization. J Invest Dermatol. 2021.
   PubMed Web of Science ®Google Scholar
• Furue M, Yamamura K, Kido-Nakahara M, et al. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2018;73(1):29–36.
   PubMed Web of Science ®Google Scholar
• Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133(2):448–460.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Nattkemper LA, Kim HS, et al. Dermal Periostin: a New Player in Itch of Prurigo Nodularis. Acta Derm Venereol. 2021;101(1):adv00375.
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Nattkemper LA, Kim HS, et al. Itch intensity in prurigo nodularis is closely related with dermal interleukin-31, oncostatin M, IL-31 receptor alpha, and oncostatin M receptor beta. Exp Dermatol. 2021;30(6):804–810.
   PubMed Web of Science ®Google Scholar
• Meng J, Moriyama M, Feld M, et al. New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol. 2018;141(1677–1689):e8.
   Google Scholar
• Maier E, Werner D, Duschl A, et al. Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-κB-dependent way. J Immunol. 2014;193(2):645–654.
   PubMed Web of Science ®Google Scholar
• Mishra SK, Wheeler JJ, Pitake S, et al. Periostin Activation of Integrin Receptors on Sensory Neurons Induces Allergic Itch. Cell Rep. 2020;31(1):107472.
   PubMed Web of Science ®Google Scholar
• Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011;165(5):990–996.
   PubMed Web of Science ®Google Scholar
• Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5–14.
   PubMed Web of Science ®Google Scholar
• Oetjen LK, Mack MR, Feng J, et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. Cell. 2017;171(217–228):e13.
   Google Scholar
• Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: united States expert panel consensus. J Am Acad Dermatol. 2021 Mar;84(3):747–760.
   PubMed Web of Science ®Google Scholar
• Zeidler C, Ständer S. Therapie der Prurigo nodularis. Hautarzt. 2014;65(8):709–713.
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k Guideline on Chronic Pruritus. Acta Derm Venereol. 2019;99(5):469–506.
   PubMed Web of Science ®Google Scholar
• Gründel S, Pereira MP, Storck M, et al. Analysis of 325 Patients with Chronic Nodular Prurigo: clinics, Burden of Disease and Course of Treatment. Acta Derm Venereol. 2020;100(16):adv00269.
   PubMed Web of Science ®Google Scholar
• Tsianakas A, Zeidler C, Prurigo Nodularis SS. Management. Curr Probl Dermatol. 2016;50:94–101.
   PubMedGoogle Scholar
• Maredia H, Kwatra SG. Emerging novel therapeutic agents for the treatment of patients with prurigo nodularis. J Dermatolog Treat. 2020;1–4.
   PubMed Web of Science ®Google Scholar
• Ständer S, Pereira MP, Berger T, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42–e42.
   Google Scholar
• Zeidler C, Pereira M, The Neuromodulatory SS. Effect of Antipruritic Treatment of Chronic Prurigo. Dermatol Ther (Heidelb). 2019;9(4):613–622.
   PubMed Web of Science ®Google Scholar
• Ohanyan T, Schoepke N, Eirefelt S, et al. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: a Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant. Acta Derm Venereol. 2018;98(1):26–31.
   PubMed Web of Science ®Google Scholar
• Erickson S, Nahmias Z, Rosman IS, et al. Immunomodulating Agents as Antipruritics. Dermatol Clin. 2018;36(3):325–334.
   PubMed Web of Science ®Google Scholar
• Erickson S, Ver Heul A, Kim BS. New and emerging treatments for inflammatory itch. Ann Allergy Asthma Immunol. 2021;126(1):13–20.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: a Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44–56.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Beck KM, Yang EJ, Sekhon S, et al. Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatol. 2019;155(1):118–120.
   PubMed Web of Science ®Google Scholar
• Calugareanu A, Jachiet M, Tauber M, et al. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. J Eur Acad Dermatol Venereol. 2020;34(2):e74–e76.
   PubMed Web of Science ®Google Scholar
• Calugareanu A, Jachiet M, Lepelletier C, et al. Dramatic improvement of generalized prurigo nodularis with dupilumab. J Eur Acad Dermatol Venereol. 2019;33(8):e303–e304.
   PubMed Web of Science ®Google Scholar
• Fachler T, Maria Faitataziadou S, Molho-Pessach V. Dupilumab for pediatric prurigo nodularis: a case report. Pediatr Dermatol. 2021 Jan;38(1):334–335.
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Tavecchio S, Berti E, et al. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy. J Dermatolog Treat. 2021 Jun;32(4):453–454.
   PubMed Web of Science ®Google Scholar
• Holm JG, Agner T, Sand C, et al. Dupilumab for prurigo nodularis: case series and review of the literature. Dermatol Ther. 2020;33(2):e13222.
   PubMed Web of Science ®Google Scholar
• Giura MT, Viola R, Fierro MT, et al. Efficacy of dupilumab in prurigo nodularis in elderly patient. Dermatol Ther. 2020;33:e13201.
   PubMed Web of Science ®Google Scholar
• Kovács B, Rose E, Kuznik N, et al. Dupilumab for treatment-refractory prurigo nodularis. J Dtsch Dermatol Ges. 2020;18:618–624.
   Web of Science ®Google Scholar
• Rambhia PH, Levitt JO. Recalcitrant prurigo nodularis treated successfully with dupilumab. JAAD Case Rep. 2019;5(5):471–473.
   PubMedGoogle Scholar
• Romano C. Safety and Effectiveness of Dupilumab in Prurigo Nodularis. J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):162–163.
   PubMed Web of Science ®Google Scholar
• Husein-ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat. 2020;1–7.
   PubMed Web of Science ®Google Scholar
• Mollanazar NK, Elgash M, Weaver L, et al. Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis. JAMA Dermatol. 2019;155(1):121–122.
   PubMed Web of Science ®Google Scholar
• Wieser JK, Mercurio MG, Somers K. Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: a Case Series. Cureus. 2020;12:e8737.
   PubMed Web of Science ®Google Scholar
• Bieber T. Interleukin- 13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62.
   PubMed Web of Science ®Google Scholar
• Mitamura Y, Nunomura S, Nanri Y, et al. The IL-13/periostin/IL-24 pathway causes epidermal barrier dysfunction in allergic skin inflammation. Allergy. 2018;73(9):1881–1891.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437–449.
   Google Scholar
• Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: a Phase 2b Randomized Clinical Trial. JAMA Dermatol. 2020;156(4):411–420.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(863–871):e11.
   PubMed Web of Science ®Google Scholar
• Ständer S, Weisshaar E, Raap U. Emerging drugs for the treatment of pruritus. Expert Opin Emerg Drugs. 2015;20(3):515–521.
   PubMed Web of Science ®Google Scholar
• Richards CD, Gandhi R, Botelho F, et al. Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716. Acta Derm Venereol. 2020;100(14):adv00197.
   PubMed Web of Science ®Google Scholar
• Zeidler C, Pereira MP, Augustin M, et al. Investigator’s Global Assessment of Chronic Prurigo: a New Instrument for Use in Clinical Trials. Acta Derm Venereol. 2021;101(2):adv00401.
   PubMed Web of Science ®Google Scholar
• Grieco T, Chello C, Faina V, et al. Omalizumab therapy in a patient with cronic spontaneous urticaria, ulcerative colitis, hypereosinophilia and prurigo Besnier: a case report. J Dermatolog Treat. 2018;29(sup3):10–13.
   PubMed Web of Science ®Google Scholar
• Ugajin T, Inazawa M, Inui K, et al. A case of chronic prurigo successfully treated with omalizumab. Eur J Dermatol. 2018;28:691–692.
   PubMed Web of Science ®Google Scholar
• Ito Y, Satoh T, Takayama K, et al. Basophil recruitment and activation in inflammatory skin diseases. Allergy. 2011;66(8):1107–1113.
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosén K, Hsieh H. J et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935.
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67–75.
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89(6–7):884–893.
   PubMed Web of Science ®Google Scholar
• Noh G, Lee KY. Successful interferon alpha therapy in atopic dermatitis of Besnier’s prurigo pattern with normal serum IgE and blood eosinophil fraction: randomized case-controlled study. Cytokine. 2001;13(2):124–128.
   PubMed Web of Science ®Google Scholar
• Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(S3):112S–121S.
   PubMed Web of Science ®Google Scholar
• Hawi A, Alcorn H, Berg J, et al. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol. 2015;16(1):47.
   PubMed Web of Science ®Google Scholar
• Jannuzzi RG. Nalbuphine for Treatment of Opioid-induced Pruritus: a Systematic Review of Literature. Clin J Pain. 2016;32(1):87–93.
   PubMed Web of Science ®Google Scholar
• Inan S, Cowan A. Antipruritic Effects of Kappa Opioid Receptor Agonists: evidence from Rodents to Humans. Handb Exp Pharmacol. 2020. Epub ahead of print.
   PubMedGoogle Scholar
• Reich K, DeLozier AM, Nunes FP, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2020 1:10
   Web of Science ®Google Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase II a randomized trial. Br J Dermatol. 2016;175(5):902–911.
   PubMed Web of Science ®Google Scholar
• He Y, Ji S, Yu Q. Effectiveness of baricitinib in prurigo-type atopic dermatitis: a case report. Dermatol Ther. 2021;34(2):e14878.
   Google Scholar